L-Selectin/CD62L Antibody (FMC46)
Novus Biologicals, part of Bio-Techne | Catalog # NB100-65388
Clone FMC46 was used by HLDA to establish CD designation.
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Bovine
Applications
Validated:
Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, Immunoprecipitation
Cited:
Flow (Cell Surface)
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2B Clone # FMC46
Concentration
1.0 mg/ml
Product Specifications
Immunogen
PHA stimulated lymphoblasts
Reactivity Notes
Predicted cross-reactivities: Cynomolgus monkey, Dog, Bovine, Rhesus Monkey
Localization
Membrane; single pass type I membrane protein.
Specificity
NB100-65388 recognizes human CD62L, also known a L-selectin, a 74-95kDa member of the selectin family of adhesion receptors, which acts as a ligand for both CD62-P (P-selectin) and CD62E (E-selectin). Human CD62L is constitutively expressed on most leucocytes including monocytes, granulocytes, lymphocytes, NK cells, bone marrow myeloid progenitor cells and on a subset of thymocytes. CD62L plays an important role in leucocyte tethering and rolling on the endothelial cell surface and for the homing of naive lymphocytes to lymph nodes and Peyers patches via HEV. Neutrophils require a constant supply of this molecule on the cell surface for migration into peripheral tissues and adhesion to activated endothelium at sites of inflammation, where CD62L is rapidly shed as soluble L-selectin, but surface expression still remains. The expression of CD62L is down regulated on lymphocytes and neutrophils by PMA stimulation.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Scientific Data Images for L-Selectin/CD62L Antibody (FMC46)
Flow Cytometry: L-Selectin/CD62L Antibody (FMC46) - BSA Free [NB100-65388]
Flow Cytometry: L-Selectin/CD62L Antibody (FMC46) [NB100-65388] - Flow Cytometry: L-Selectin/CD62L Antibody (FMC46) [PerCP] [NB100-65388PCP] - A cell surface stain was performed on human peripheral blood lymphocytes with L-Selectin/CD62L (FMC46) antibody NB100-65388PCP (blue) and a matched isotype control NBP2-27231PCP (orange). Cells were incubated in an antibody dilution of 5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Peridinin-Chlorophyll-Protein complex. Image using the PerCP form of this antibody.Flow Cytometry: L-Selectin/CD62L Antibody (FMC46) - BSA Free [NB100-65388]
Flow Cytometry: L-Selectin/CD62L Antibody (FMC46) [NB100-65388] - Staining of human peripheral blood granulocytes with Mouse anti Human CD62L:FITCApplications for L-Selectin/CD62L Antibody (FMC46)
Application
Recommended Usage
Flow Cytometry
1:50-1:100
Immunohistochemistry
1:10-1:500
Immunohistochemistry-Frozen
1:10-1:500
Immunoprecipitation
1:10-1:500
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.09% Sodium Azide
Concentration
1.0 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: L-Selectin/CD62L
L-selectin expressed on leukocytes binds to ligands expressed by endothelial cells where it plays a role in lymphocyte homing to secondary lymphoid organs (2-5). L-selectin specifically recognizes and binds to sulfated sialyl-Lewis epitopes of O-linked glycans (2-4). Ligands for L-selectin include glycosylation-dependent cell adhesion molecule-1 (GlyCAM-1), CD34, mucosal vascular addressin cell adhesion molecule-1 (MAdCAM-1), and P-selectin glycoprotein ligand-1 (PSGL-1) (2,4). Elevated levels of selectin ligands on tumor cells are associated with cancer progression and metastasis (3). High levels of L-selectin and soluble L-selectin (sL-selectin) has been implicated in a number of pathologies from viral infection and allergies, to sepsis and multiple sclerosis (2,4,5). For example, L-selectin has been shown to play a role in human immunodeficiency virus (HIV) infection. HIV envelope glycans, such as gp120, binds to L-selectin/CD62L on CD4+ T cells, facilitating viral adhesion (2,5). A disintegrin and metalloproteinase (ADAM)17 is the primary enzyme responsible for L-selectin shedding in leukocytes, which is triggered in response to inflammatory signals (1,2,5). AMAD17 inhibitors block L-selectin shedding and reduce viral release (2,5). Given their role in cancer and other diseases, selectins and their ligands are potential targets for therapeutic intervention (3,5). For instance, murine models have shown that anti-L-selectin antibodies can delay onset of graft versus host disease (5).
References
1. Ivetic A. (2018). A head-to-tail view of L-selectin and its impact on neutrophil behaviour. Cell and Tissue Research, 371(3), 437-453. https://doi.org/10.1007/s00441-017-2774-x
2. Ivetic, A., Hoskins Green, H. L., & Hart, S. J. (2019). L-selectin: a major regulator of leukocyte adhesion, migration and signaling. Frontiers in Immunology, 10, 1068. https://doi.org/10.3389/fimmu.2019.01068
3. Borsig L. (2018). Selectins in cancer immunity. Glycobiology, 28(9), 648-655. https://doi.org/10.1093/glycob/cwx105
4. Kneuer, C., Ehrhardt, C., Radomski, M. W., & Bakowsky, U. (2006). Selectins-potential pharmacological targets?. Drug Discovery Today, 11(21-22), 1034-1040. https://doi.org/10.1016/j.drudis.2006.09.004
5. Segura, J., He, B., Ireland, J., Zou, Z., Shen, T., Roth, G., & Sun, P. D. (2021). The role of L-Selectin in HIV infection. Frontiers in Microbiology, 12, 725741. https://doi.org/10.3389/fmicb.2021.725741
Alternate Names
CD62L, hLHRc, LAM1, LECAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR, SELL, TQ1
Entrez Gene IDs
6402 (Human)
Gene Symbol
SELL
UniProt
Additional L-Selectin/CD62L Products
Product Documents for L-Selectin/CD62L Antibody (FMC46)
Product Specific Notices for L-Selectin/CD62L Antibody (FMC46)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...